Copycat to top-selling eye drug takes a step toward market

The FDA is reviewing Samsung Bioepis and Biogen's biosimilar of Lucentis. If approved, it would be the first biosimilar for an eye disease drug.

By Kristin Jensen • Nov. 18, 2020

Finding the right mix: Digital transformation offers opportunities for improved HCP engagement

Field teams and HCPs alike are learning how digital, data-driven approaches can best support safe, productive engagement.

Nov. 9, 2020

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Trump administration to require insurers cover coronavirus vaccines

Late-stage vaccine results are expected soon from Pfizer and Moderna, putting pressure on the Trump administration to put in motion plans for what's likely to be a complex and challenging distribution process.

By Shannon Muchmore • Oct. 29, 2020

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

By Kristin Jensen • Oct. 27, 2020

Facing vaccine doubts, US grapples with building confidence in coronavirus shots

The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA last week.

By Jonathan Gardner • Oct. 22, 2020

Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales

Under a deal reached with the Department of Justice, Purdue faces fines and a forfeiture worth more than $5 billion — the largest penalties ever for a drug company.

By Jacob Bell • Oct. 21, 2020

Doctors are consumers too! How DTC media impacts HCPs

The findings have implications for how pharma teams should think about their DTC and HCP efforts — they are no longer two separate marketing channels.

Oct. 19, 2020

Nestlé​ makes newly acquired Aimmune a stand-alone unit, appoints new CEO

Andrew Oxtoby, formerly chief commercial officer at the peanut allergy drugmaker, will take over as head of the new Nestlé business.

By Kristin Jensen • Oct. 14, 2020

FDA moves to pull preterm birth drug from market

AMAG Pharma, the maker of Makena, said the company disagreed with the FDA's proposal and plans to evaluate its options following a failed study.

By Kristin Jensen • Oct. 7, 2020

Achieving success in pharma marketing: The need for a personalized, omnichannel approach

Personalized, insight-driven omnichannel marketing has never been more beneficial or important. 

Oct. 7, 2020

After setback in the US, Galapagos' main drug finds success elsewhere

A month after the FDA surprisingly rejected the rheumatoid arthritis drug, called filgotinib, it's been cleared by regulators in Europe and Japan.

By Jacob Bell • Sept. 28, 2020

Health insurer sues Indivior over 'profit protection scheme'

Centene aims to recoup money it paid for Indivior's Suboxone product, alleging the drugmaker devised a plan to box out generic competitors.

By Samantha Liss • Updated Sept. 23, 2020

Cigna rebrands health services division, including Express Scripts, as Evernorth

The change, which has been in the works since before the pandemic, is the next step in integrating the companies' business since their merger in 2018.

By Rebecca Pifer • Sept. 16, 2020

Hospitals urge HHS to step in on 340B fight with drugmakers

The dispute stems from drugmakers deciding to stop giving 340B discounts to contract pharmacies, which many hospitals use.

By Shannon Muchmore • Sept. 9, 2020

Thermo Fisher deal for Qiagen falls apart after companies fail to secure investor backing

Thermo Fisher had raised its bid for Qiagen to about $12.5 billion, but less than half of the company's shares were tendered by the offer's expiration Monday.

By Nick Paul Taylor , Maria Rachal , Greg Slabodkin • Updated Aug. 13, 2020

Bristol Myers pledges to spend $300M on addressing racial, health disparities

The drugmaker aims to double Black and Latinx representation in its executive ranks, among other commitments.

By Kristin Jensen • Aug. 12, 2020

First liquid biopsy test that uses advanced gene sequencing approved by FDA

The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test.

By Susan Kelly • Aug. 10, 2020

Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future

Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.

By Ben Fidler • Aug. 4, 2020

Biogen points to COVID-19 for disappointing drug launch

Sales of Vumerity, a key new product in Biogen's plan to bolster its multiple sclerosis drug business, have been slow since it launched in December.

By Jacob Bell • July 22, 2020

Ohio sues Express Scripts for overcharging state pension fund

"We want our money back," attorney general Dave Yost said, arguing Express Scripts "egregiously charged for services it didn't deliver." It's the latest action taken by the state against pharmacy benefit managers. 

By Samantha Liss • July 15, 2020

AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says

More than seven dozen patents have been granted for Imbruvica in the U.S., helping AbbVie create a legal defense that could protect the drug until 2036. 

By Kristin Jensen • July 15, 2020

4 months with COVID-19: Impact on US health and media behaviors

To help pharmaceutical companies navigate the volatile industry landscape, Crossix has continued to monitor country-wide health and media behaviors.

July 14, 2020

Providers, insurers back ad campaign urging patients to stop 'medical distancing'

Since the pandemic's onset in the United States, health officials have been concerned about the consequences of routine and preventive care being delayed or put off entirely. Providers also fear further revenue loss.

By Shannon Muchmore • July 8, 2020

Novartis to pay $678M to settle claims over 'sham' doctor events

The Swiss drugmaker admitted to hosting lavish dinners and events that were intended to convince doctors to prescribe Novartis heart and diabetes drugs.

By Ned Pagliarulo • July 2, 2020

Gilead pricing suggests it will make a business out of COVID-19 drug

Even at the lower end of its price range, remdesivir could earn Gilead a billion dollars. How well the drug's price is received will be an important test for other companies working on coronavirus treatments.

By Jacob Bell • June 30, 2020